Acceleron Pharma (XLRN) PT Lowered to $68 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) PT Lowered to $58 at Oppenheimer
September 17, 2019 7:23 AM EDTOppenheimer analyst Leland Gershell lowered the price target on Acceleron Pharma (NASDAQ: XLRN) to $58.00 (from $59.00) while maintaining a Outperform rating.
... MoreAcceleron Pharma (XLRN) PT Lowered to $52 at Citi
September 17, 2019 5:21 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on Acceleron Pharma (NASDAQ: XLRN) to $52.00 (from $61.00) while maintaining a Buy rating.
... MoreAfter-Hours Movers 09/16: (ACRS) Higher; (FNKO) (XLRN) (DRQ) Lower (more...)
September 16, 2019 5:23 PM EDTToday's After-Hours Movers
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 50.9% HIGHER; announced positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution (A-101 45% Topical Solution), an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the primary and all secondary efficacy endpoints, achieving clinically and... More
Acceleron Pharma (XLRN) Phase 2 Trial of ACE-083 in Patients with FSHD Did Not Achieve Functional Secondary Endpoints
September 16, 2019 4:31 PM EDTAcceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.
Although ACE-083 demonstrated a robust, statistically significant increase in mean total muscle volume, the primary endpoint of the trial, the increase failed to translate to statistically significant improvements in functional tests. As a result, Acceleron will not conduct further clinical trials of ACE-083 in... More
